SPY376.70-4.72 -1.24%
DIA309.58-3.41 -1.09%
IXIC12,723.47-274.28 -2.11%

Press Release: Gilead Sciences Announces Fourth -9-

· 02/04/2021 16:01
CONTACT: Investors-------------------- -------- -------- -------- --------- GILEAD SCIENCES, INC. PRODUCT SALES SUMMARY - (Continued) (unaudited) Three Months Ended Twelve Months Ended December 31, December 31, -------------- --------------------- 2020 2019 2020 2019 ------------------ ------ ------ ---------- --------- Other Products ------------------ AmBisome -- U.S. 15 10 61 37 AmBisome -- Europe 64 60 230 234 AmBisome -- Other International 32 40 145 136 ------ ------ ---------- ------- 111 110 436 407 ------ ------ ---------- ------- Letairis -- U.S. 73 96 314 618 ------ ------ ---------- ------- Ranexa -- U.S. -- 11 9 216 ------ ------ ---------- ------- Vemlidy -- U.S. 108 95 356 309 Vemlidy -- Europe 7 6 29 21 Vemlidy -- Other International 78 36 272 158 ------ ------ ---------- ------- 193 137 657 488 ------ ------ ---------- ------- Viread -- U.S. 4 4 14 32 Viread -- Europe 7 12 34 69 Viread -- Other International 37 23 137 142 ------ ------ ---------- ------- 48 39 185 243 ------ ------ ---------- ------- Zydelig -- U.S. 7 11 31 47 Zydelig -- Europe 9 12 39 54 Zydelig -- Other International 1 1 2 2 ------ ------ ---------- ------- 17 24 72 103 ------ ------ ---------- ------- Other(6) -- U.S. 34 34 146 153 Other(6) -- Europe 15 13 53 52 Other(6) -- Other International 7 3 14 9 ------ ------ ---------- ------- 56 50 213 214 ------ ------ ---------- ------- Total Other -- U.S. 241 261 931 1,412 Total Other -- Europe 102 103 385 430 Total Other -- Other International 155 103 570 447 ------ ------ ---------- ------- 498 467 1,886 2,289 ------ ------ ---------- ------- Total product sales -- U.S. 5,306 4,516 18,141 16,565 Total product sales -- Europe 1,366 840 3,894 3,567 Total product sales -- Other International 656 440 2,320 1,987 ------ ------ ---------- ------- $7,328 $5,796 $ 24,355 $22,119 ===== ===== ====== ====== ______________________ (1) Represents Gilead's revenue from cobicistat (C), emtricitabine (FTC) and tenofovir alafenamide (TAF) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland UC. (2) Includes Emtriva and Tybost. (3) Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by Gilead's separate subsidiary, Asegua Therapeutics LLC. (4) Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by Gilead's separate subsidiary, Asegua Therapeutics LLC. (5) Includes Vosevi and Sovaldi. The period-over-period changes in Europe and Other International locations were primarily due to adjustments for statutory rebates related to sales of Sovaldi made in prior years. (6) Includes Cayston, Hepsera and Jyseleca. (7) Trodelvy sales for the fourth quarter and full year 2020, including the period prior to the completion of Gilead's acquisition of Immunomedics, were $64 million and $137 million, respectively.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210204006011/en/

Jacquie Ross

(650) 574-3000

Media

Amy Flood

(650) 522-5643

(END) Dow Jones Newswires

February 04, 2021 16:01 ET (21:01 GMT)